1
|
García Á, Aslan JE. Special review series: provocative questions in platelet omics studies. Platelets 2023; 34:2259169. [PMID: 37726881 DOI: 10.1080/09537104.2023.2259169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023]
Affiliation(s)
- Ángel García
- Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, and Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
| | - Joseph E Aslan
- Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA
- Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, OR, USA
- Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, USA
| |
Collapse
|
2
|
Dai X, Shen L. Advances and Trends in Omics Technology Development. Front Med (Lausanne) 2022; 9:911861. [PMID: 35860739 PMCID: PMC9289742 DOI: 10.3389/fmed.2022.911861] [Citation(s) in RCA: 81] [Impact Index Per Article: 40.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2022] [Accepted: 05/09/2022] [Indexed: 12/11/2022] Open
Abstract
The human history has witnessed the rapid development of technologies such as high-throughput sequencing and mass spectrometry that led to the concept of “omics” and methodological advancement in systematically interrogating a cellular system. Yet, the ever-growing types of molecules and regulatory mechanisms being discovered have been persistently transforming our understandings on the cellular machinery. This renders cell omics seemingly, like the universe, expand with no limit and our goal toward the complete harness of the cellular system merely impossible. Therefore, it is imperative to review what has been done and is being done to predict what can be done toward the translation of omics information to disease control with minimal cell perturbation. With a focus on the “four big omics,” i.e., genomics, transcriptomics, proteomics, metabolomics, we delineate hierarchies of these omics together with their epiomics and interactomics, and review technologies developed for interrogation. We predict, among others, redoxomics as an emerging omics layer that views cell decision toward the physiological or pathological state as a fine-tuned redox balance.
Collapse
|
3
|
Shevchuk O, Begonja AJ, Gambaryan S, Totzeck M, Rassaf T, Huber TB, Greinacher A, Renne T, Sickmann A. Proteomics: A Tool to Study Platelet Function. Int J Mol Sci 2021; 22:ijms22094776. [PMID: 33946341 PMCID: PMC8125008 DOI: 10.3390/ijms22094776] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Revised: 04/22/2021] [Accepted: 04/22/2021] [Indexed: 12/22/2022] Open
Abstract
Platelets are components of the blood that are highly reactive, and they quickly respond to multiple physiological and pathophysiological processes. In the last decade, it became clear that platelets are the key components of circulation, linking hemostasis, innate, and acquired immunity. Protein composition, localization, and activity are crucial for platelet function and regulation. The current state of mass spectrometry-based proteomics has tremendous potential to identify and quantify thousands of proteins from a minimal amount of material, unravel multiple post-translational modifications, and monitor platelet activity during drug treatments. This review focuses on the role of proteomics in understanding the molecular basics of the classical and newly emerging functions of platelets. including the recently described role of platelets in immunology and the development of COVID-19.The state-of-the-art proteomic technologies and their application in studying platelet biogenesis, signaling, and storage are described, and the potential of newly appeared trapped ion mobility spectrometry (TIMS) is highlighted. Additionally, implementing proteomic methods in platelet transfusion medicine, and as a diagnostic and prognostic tool, is discussed.
Collapse
Affiliation(s)
- Olga Shevchuk
- Leibniz-Institut für Analytische Wissenschaften—ISAS—e.V, Bunsen-Kirchhoff-Straße 11, 44139 Dortmund, Germany
- Department of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
- Correspondence: (O.S.); (A.S.)
| | - Antonija Jurak Begonja
- Department of Biotechnology, University of Rijeka, Radmile Matejčić 2, 51000 Rijeka, Croatia;
| | - Stepan Gambaryan
- Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Torez pr. 44, 194223 St. Petersburg, Russia;
| | - Matthias Totzeck
- West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany; (M.T.); (T.R.)
| | - Tienush Rassaf
- West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany; (M.T.); (T.R.)
| | - Tobias B. Huber
- III. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany;
| | - Andreas Greinacher
- Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Sauerbruchstraße, 17475 Greifswald, Germany;
| | - Thomas Renne
- Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany;
| | - Albert Sickmann
- Leibniz-Institut für Analytische Wissenschaften—ISAS—e.V, Bunsen-Kirchhoff-Straße 11, 44139 Dortmund, Germany
- Medizinisches Proteom-Center (MPC), Medizinische Fakultät, Ruhr-Universität Bochum, 44801 Bochum, Germany
- Department of Chemistry, College of Physical Sciences, University of Aberdeen, Aberdeen AB24 3FX, UK
- Correspondence: (O.S.); (A.S.)
| |
Collapse
|
4
|
Veenstra TD. Omics in Systems Biology: Current Progress and Future Outlook. Proteomics 2021; 21:e2000235. [PMID: 33320441 DOI: 10.1002/pmic.202000235] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 11/25/2020] [Indexed: 12/16/2022]
Abstract
Biological research has undergone tremendous changes over the past three decades. Research used to almost exclusively focus on a single aspect of a single molecule per experiment. Modern technologies have enabled thousands of molecules to be simultaneously analyzed and the way that these molecules influence each other to be discerned. The change is so dramatic that it has given rise to a whole new descriptive suffix (i.e., omics) to describe these fields of study. While genomics was arguably the initial driver of this new trend, it quickly spread to other biological entities resulting in the creation of transcriptomics, proteomics, metabolomics, etc. The development of these "big four omics" created a wave of other omic fields, such as epigenomics, glycomics, lipidomics, microbiomics, and even foodomics; all with the purpose of comprehensively studying all the molecular entities or processes within their respective domain. The large number of omic fields that are invented even led to the term "panomics" as a way to classify them all under one category. Ultimately, all of these omic fields are setting the foundation for developing systems biology; in which the focus will be on determining the complex interactions that occur within biological systems.
Collapse
|
5
|
Khodadi E. Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules. Cardiovasc Toxicol 2020; 20:1-10. [PMID: 31784932 DOI: 10.1007/s12012-019-09555-4] [Citation(s) in RCA: 68] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Globally, one of the major causes of death is the cardiovascular disease (CVD), and platelets play an important role in thrombosis and atherosclerosis that led to death. Platelet activation can be done by different molecules, genes, pathways, and chemokines. Lipids activate platelets by inflammatory factors, and platelets are activated by receptors of peptide hormones, signaling and secreted proteins, microRNAs (miRNAs), and oxidative stress which also affect the platelet activation in older age. In addition, surface molecules on platelets can interact with other cells and chemokines in activated platelets and cause inflammation thrombosis events and CVD. However, these molecules activating platelets or being activated by platelets can be suggested as the markers to predict the clinical outcome of CVD and can be targeted to reduce thrombosis and atherosclerosis. However, hindering these molecules by other factors such as genes and receptors can reduce platelet activation and aggregation and targeting these molecules can control platelet interactions, thrombosis, and CVD. In addition, dual therapy with the receptor blockers and novel drugs results in better management of CVD patients. Overall, our review will emphasize on the molecules involved in the activation of platelets and on the molecules that are activated by platelets in CVD and discuss the molecules that can be blocked or targeted to reduce the thrombosis events and control CVD.
Collapse
Affiliation(s)
- Elahe Khodadi
- Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
| |
Collapse
|
6
|
Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics. Int J Mol Sci 2020; 21:ijms21124541. [PMID: 32630608 PMCID: PMC7352998 DOI: 10.3390/ijms21124541] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 06/15/2020] [Accepted: 06/24/2020] [Indexed: 12/16/2022] Open
Abstract
Platelets are a heterogeneous small anucleate blood cell population with a central role both in physiological haemostasis and in pathological states, spanning from thrombosis to inflammation, and cancer. Recent advances in proteomic studies provided additional important information concerning the platelet biology and the response of platelets to several pathophysiological pathways. Platelets circulate systemically and can be easily isolated from human samples, making proteomic application very interesting for characterizing the complexity of platelet functions in health and disease as well as for identifying and quantifying potential platelet proteins as biomarkers and novel antiplatelet therapeutic targets. To date, the highly dynamic protein content of platelets has been studied in resting and activated platelets, and several subproteomes have been characterized including platelet-derived microparticles, platelet granules, platelet releasates, platelet membrane proteins, and specific platelet post-translational modifications. In this review, a critical overview is provided on principal platelet proteomic studies focused on platelet biology from signaling to granules content, platelet proteome changes in several diseases, and the impact of drugs on platelet functions. Moreover, recent advances in quantitative platelet proteomics are discussed, emphasizing the importance of targeted quantification methods for more precise, robust and accurate quantification of selected proteins, which might be used as biomarkers for disease diagnosis, prognosis and therapy, and their strong clinical impact in the near future.
Collapse
|
7
|
Vögtle T, Baig AA, Volz J, Duchow TB, Pleines I, Dütting S, Nitschke L, Watson SP, Nieswandt B. Critical redundant functions of the adapters Grb2 and Gads in platelet (hem)ITAM signaling in mice. Platelets 2020; 31:801-811. [DOI: 10.1080/09537104.2019.1709633] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Timo Vögtle
- Institute of Experimental Biomedicine I, University Hospital Würzburg and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany
| | - Ayesha A. Baig
- Institute of Experimental Biomedicine I, University Hospital Würzburg and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany
| | - Julia Volz
- Institute of Experimental Biomedicine I, University Hospital Würzburg and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany
| | - Timothy B. Duchow
- Institute of Experimental Biomedicine I, University Hospital Würzburg and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany
| | - Irina Pleines
- Institute of Experimental Biomedicine I, University Hospital Würzburg and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany
| | - Sebastian Dütting
- Institute of Experimental Biomedicine I, University Hospital Würzburg and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany
| | - Lars Nitschke
- Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany
| | - Stephen P. Watson
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
- Centre of Membrane Proteins and Receptors (COMPARE), Universities of Birmingham and Nottingham, The Midlands, UK
| | - Bernhard Nieswandt
- Institute of Experimental Biomedicine I, University Hospital Würzburg and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany
| |
Collapse
|
8
|
Comparative proteomics reveals unexpected quantitative phosphorylation differences linked to platelet activation state. Sci Rep 2019; 9:19009. [PMID: 31831789 PMCID: PMC6908631 DOI: 10.1038/s41598-019-55391-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Accepted: 11/23/2019] [Indexed: 01/26/2023] Open
Abstract
There is a need to assess platelet activation in patients with thrombotic disorders. P-selectin and activated integrin αIIbβ3 are usually quantified by flow cytometry to measure platelet activation. Monitoring changes in vasodilator-stimulated phosphoprotein (VASP) phosphorylation is an established method to determine the platelet-reactivity status. To study disruptions of platelet reactivity more comprehensively, we compared the human non-secretory platelet proteome after in-vitro -activation and -inhibition with their respective untreated controls using unbiased fluorescence two-dimensional differential in-gel electrophoresis. The non-secretory platelet proteome was more severely affected during inhibition than during activation. Strikingly, while VASP reached a 1.3-fold increase in phosphorylation levels in inhibited platelets, other protein kinase A targets showed several-fold stronger inhibition-induced phosphorylation levels, including LIM and SH3 domain protein 1 (6.7-fold), Src kinase-associated phosphoprotein 2 (4.6-fold), and Ras-related protein Rap1b (4.1-fold). Moreover, phosphorylation of integrin-linked protein kinase (ILK) and pleckstrin (PLEK) species was associated with P-selectin surface expression. The discrimination power between activation and inhibition was more pronounced for dephosphorylated ILK (3.79 Cohen's d effect size) and phosphorylated PLEK (3.77) species than for P-selectin (2.35). These data reveal new insights into the quantitative changes of the platelet reactivity proteome and suggest powerful alternatives to characterise their activation and inactivation potential.
Collapse
|
9
|
Proteomic profiling of the thrombin-activated canine platelet secretome (CAPS). PLoS One 2019; 14:e0224891. [PMID: 31721811 PMCID: PMC6853320 DOI: 10.1371/journal.pone.0224891] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Accepted: 10/23/2019] [Indexed: 11/27/2022] Open
Abstract
Domestic dogs share the same environment as humans, and they represent a valuable animal model to study naturally-occurring human disease. Platelet proteomics holds promise for the discovery of biomarkers that capture the contribution of platelets to the pathophysiology of many disease states, however, canine platelet proteomic studies are lacking. Our study objectives were to establish a protocol for proteomic identification and quantification of the thrombin-activated canine platelet secretome (CAPS), and to compare the CAPS proteins to human and murine platelet proteomic data. Washed platelets were isolated from healthy dogs, and stimulated with saline (control) or gamma-thrombin (releasate). Proteins were separated by SDS-page, trypsin-digested and analyzed by liquid chromatography and tandem mass spectrometry (MS). CAPS proteins were defined as those with a MS1-abundance ratio of two or more for releasate vs. unstimulated saline control. A total of 1,918 proteins were identified, with 908 proteins common to all dogs and 693 characterized as CAPS proteins. CAPS proteins were similar to human and murine platelet secretomes and were highly represented in hemostatic pathways. Differences unique to CAPS included replacement of platelet factor 4 with other cleavage products of platelet basic protein (e.g. interleukin-8), novel proteins (e.g. C-C motif chemokine 14), and proteins in relatively high (e.g. protease nexin-1) or low (e.g. von Willebrand factor) abundance. This study establishes the first in-depth platelet releasate proteome from healthy dogs with a reference database of 693 CAPS proteins. Similarities between CAPS and the human secretome confirm the utility of dogs as translational models of human disease, but we also identify differences unique to canine platelets. Our findings provide a resource for further investigations into disease-related CAPS profiles, and for comparative pathway analyses of platelet activation among species.
Collapse
|
10
|
Looße C, Swieringa F, Heemskerk JWM, Sickmann A, Lorenz C. Platelet proteomics: from discovery to diagnosis. Expert Rev Proteomics 2018; 15:467-476. [PMID: 29787335 DOI: 10.1080/14789450.2018.1480111] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Platelets are the smallest cells within the circulating blood with key roles in physiological hemostasis and pathological thrombosis regulated by the onset of activating/inhibiting processes via receptor responses and signaling cascades. Areas covered: Proteomics as well as genomic approaches have been fundamental in identifying and quantifying potential targets for future diagnostic strategies in the prevention of bleeding and thrombosis, and uncovering the complexity of platelet functions in health and disease. In this article, we provide a critical overview on current functional tests used in diagnostics and the future perspectives for platelet proteomics in clinical applications. Expert commentary: Proteomics represents a valuable tool for the identification of patients with diverse platelet associated defects. In-depth validation of identified biomarkers, e.g. receptors, signaling proteins, post-translational modifications, in large cohorts is decisive for translation into routine clinical diagnostics.
Collapse
Affiliation(s)
- Christina Looße
- a Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund , Germany
| | - Frauke Swieringa
- a Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund , Germany
| | - Johan W M Heemskerk
- b Department of Biochemistry , CARIM, Maastricht University , Maastricht , The Netherlands
| | - Albert Sickmann
- a Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund , Germany.,c Medizinisches Proteom-Center , Medizinische Fakultät, Ruhr-Universität Bochum , Bochum , Germany.,d Department of Chemistry, College of Physical Sciences , University of Aberdeen , Aberdeen , UK
| | - Christin Lorenz
- a Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund , Germany
| |
Collapse
|
11
|
Alteration of platelet GPVI signaling in ST-elevation myocardial infarction patients demonstrated by a combination of proteomic, biochemical, and functional approaches. Sci Rep 2016; 6:39603. [PMID: 28004756 PMCID: PMC5177944 DOI: 10.1038/srep39603] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2016] [Accepted: 11/24/2016] [Indexed: 11/30/2022] Open
Abstract
The platelet-specific collagen receptor glycoprotein VI (GPVI) is critical for the formation of arterial thrombosis in vivo. We analyzed GPVI-activated platelets from ST-elevation myocardial infarction (STEMI) patients and matched stable coronary artery disease (SCAD) controls in order to provide novel clues on the degree of involvement of GPVI signaling in the acute event. Firstly, platelets were isolated from systemic venous blood and activated with the GPVI specific agonist CRP (collagen-related peptide). STEMI and SCAD samples were compared by a phosphoproteomics approach. Validations were by immunoblotting in systemic and intracoronary blood from independent cohorts of patients. Twenty-six differentially regulated proteins were identified when comparing CRP-activated systemic platelets from STEMI and SCAD patients, 4 of which were selected for validation studies: PLCɣ2, G6f, SLP-76, and Dok-2. Immunoblot analyses showed these four proteins had higher tyrosine phosphorylation levels in response to CRP in platelets from STEMI patients, being these levels more pronounced at the culprit site of coronary artery occlusion. Moreover, platelet aggregation studies showed a higher response to GPVI agonists in STEMI patients compared to SCAD controls. In conclusion, we show an altered activation state of GPVI signaling in STEMI patients, confirming this receptor as a promising anti-thrombotic target for myocardial infarction.
Collapse
|
12
|
HBV maintains electrostatic homeostasis by modulating negative charges from phosphoserine and encapsidated nucleic acids. Sci Rep 2016; 6:38959. [PMID: 27958343 PMCID: PMC5154190 DOI: 10.1038/srep38959] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2016] [Accepted: 11/14/2016] [Indexed: 12/22/2022] Open
Abstract
Capsid assembly and stability of hepatitis B virus (HBV) core protein (HBc) particles depend on balanced electrostatic interactions between encapsidated nucleic acids and an arginine-rich domain (ARD) of HBc in the capsid interior. Arginine-deficient ARD mutants preferentially encapsidated spliced viral RNA and shorter DNA, which can be fully or partially rescued by reducing the negative charges from acidic residues or serine phosphorylation of HBc, dose-dependently. Similarly, empty capsids without RNA encapsidation can be generated by ARD hyper-phosphorylation in insect, bacteria, and human hepatocytes. De-phosphorylation of empty capsids by phosphatase induced capsid disassembly. Empty capsids can convert into RNA-containing capsids by increasing HBc serine de-phosphorylation. In an HBV replicon system, we observed a reciprocal relationship between viral and non-viral RNA encapsidation, suggesting both non-viral RNA and serine-phosphorylation could serve as a charge balance buffer in maintaining electrostatic homeostasis. In addition, by comparing the biochemistry assay results between a replicon and a non-replicon system, we observed a correlation between HBc de-phosphorylation and viral replication. Balanced electrostatic interactions may be important to other icosahedral particles in nature.
Collapse
|
13
|
Pagel O, Walter E, Jurk K, Zahedi RP. Taking the stock of granule cargo: Platelet releasate proteomics. Platelets 2016; 28:119-128. [PMID: 27928935 DOI: 10.1080/09537104.2016.1254762] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Human platelets are key players in a multitude of physiological and pathological processes. Upon activation they release cargo from different types of granules as well as microparticles in an apparently well-regulated and orchestrated manner. The resulting specific platelet releasates create microenvironments of biologically active compounds and proteins during platelet aggregation and thrombus formation, allowing efficient delivery of growth factors and immune modulators to their sites of effect and enhancing the coagulative response in a positive feedback loop. Thus, platelet releasates play a central role in the regulation of platelet homeostasis and heterotypic cell interaction. Additionally, it recently emerged that both the qualitative and quantitative composition of the releasate as well as release dynamics may be stimulus dependent and therefore more complex than expected. Mass spectrometry-based proteomics is an important asset for studying platelet releasates in vitro, as it allows not only (i) identifying released proteins, but moreover (ii) determining their quantities and the dynamics of release as well as (iii) differentially comparing releasates across a variety of conditions. Though owing to the high sensitivity and comprehensiveness of modern proteomic techniques, a thorough experimental design and a standardized and robust sample preparation are essential to obtain highly confident and reliable insights into platelet biology and pathology. Here, we review releasate proteome studies and crucial sample preparation strategies to summarize possible achievements of state-of-the-art technologies and furthermore discuss potential pitfalls and limitations. We provide a future perspective of platelet releasate proteomics including targeted analyses, post-translational modifications and multi-omics approaches that should be adopted by platelet releasate researchers due to their tremendous depth and comprehensiveness.
Collapse
Affiliation(s)
- Oliver Pagel
- a Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V ., Dortmund , Germany
| | - Elena Walter
- b Center for Thrombosis and Hemostasis (CTH) , Universitätsklinikum der Johannes Gutenberg-Universität Mainz , Mainz , Germany
| | - Kerstin Jurk
- b Center for Thrombosis and Hemostasis (CTH) , Universitätsklinikum der Johannes Gutenberg-Universität Mainz , Mainz , Germany
| | - René P Zahedi
- a Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V ., Dortmund , Germany
| |
Collapse
|
14
|
Izquierdo I, García Á. Platelet proteomics applied to the search for novel antiplatelet therapeutic targets. Expert Rev Proteomics 2016; 13:993-1006. [DOI: 10.1080/14789450.2016.1246188] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
15
|
García Á. Platelet clinical proteomics: Facts, challenges, and future perspectives. Proteomics Clin Appl 2016; 10:767-73. [PMID: 26948058 DOI: 10.1002/prca.201500125] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Revised: 02/17/2016] [Accepted: 02/29/2016] [Indexed: 11/08/2022]
Abstract
In recent years, proteomics has been applied to platelet clinical research. Platelets are small enucleated cells that play a fundamental role in hemostasis. In a pathological context, unwanted platelet activation is related to various diseases, primarily thrombosis, but also cancer metastasis, inflammation, immunity, and neurodegenerative diseases. The absence of a nucleus is one of the reasons why proteomics can be considered an ideal analytical tool for platelet research. Indeed, platelet proteomics has allowed the identification of many novel signaling proteins and receptors, several of which are being pursued as potential therapeutic targets. Encouraged by this success, several research groups have recently initiated clinical proteomics studies covering diseases where platelets are involved in some way, such as coronary artery disease, storage pool diseases, uremia, cystic fibrosis, and Alzheimer disease. The goal was to identify platelet biomarkers and drug targets that can help to improve the treatment/diagnosis of the disease and provide further mechanistic evidences of the role platelets play in the pathology. The present article will comment on the recent progress of clinical proteomics in the context of platelet research, challenges, and perspectives for the future ahead.
Collapse
Affiliation(s)
- Ángel García
- Platelet Proteomics Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, and Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
| |
Collapse
|
16
|
|
17
|
Lannan KL, Sahler J, Kim N, Spinelli SL, Maggirwar SB, Garraud O, Cognasse F, Blumberg N, Phipps RP. Breaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticles. Front Immunol 2015; 6:48. [PMID: 25762994 PMCID: PMC4327621 DOI: 10.3389/fimmu.2015.00048] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Accepted: 01/26/2015] [Indexed: 01/15/2023] Open
Abstract
Platelets are small anucleate blood cells derived from megakaryocytes. In addition to their pivotal roles in hemostasis, platelets are the smallest, yet most abundant, immune cells and regulate inflammation, immunity, and disease progression. Although platelets lack DNA, and thus no functional transcriptional activities, they are nonetheless rich sources of RNAs, possess an intact spliceosome, and are thus capable of synthesizing proteins. Previously, it was thought that platelet RNAs and translational machinery were remnants from the megakaryocyte. We now know that the initial description of platelets as "cellular fragments" is an antiquated notion, as mounting evidence suggests otherwise. Therefore, it is reasonable to hypothesize that platelet transcription factors are not vestigial remnants from megakaryocytes, but have important, if only partly understood functions. Proteins play multiple cellular roles to minimize energy expenditure for maximum cellular function; thus, the same can be expected for transcription factors. In fact, numerous transcription factors have non-genomic roles, both in platelets and in nucleated cells. Our lab and others have discovered the presence and non-genomic roles of transcription factors in platelets, such as the nuclear factor kappa β (NFκB) family of proteins and peroxisome proliferator-activated receptor gamma (PPARγ). In addition to numerous roles in regulating platelet activation, functional transcription factors can be transferred to vascular and immune cells through platelet microparticles. This method of transcellular delivery of key immune molecules may be a vital mechanism by which platelet transcription factors regulate inflammation and immunity. At the very least, platelets are an ideal model cell to dissect out the non-genomic roles of transcription factors in nucleated cells. There is abundant evidence to suggest that transcription factors in platelets play key roles in regulating inflammatory and hemostatic functions.
Collapse
Affiliation(s)
- Katie L Lannan
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Julie Sahler
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA ; Department of Biological and Environmental Engineering, Cornell University , Ithaca, NY , USA
| | - Nina Kim
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Sherry L Spinelli
- Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Sanjay B Maggirwar
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Olivier Garraud
- Faculté de Médecine, Université de Lyon , Saint-Etienne , France
| | - Fabrice Cognasse
- Faculté de Médecine, Université de Lyon , Saint-Etienne , France ; Etablissement Français du Sang Auvergne-Loire , Saint-Etienne , France
| | - Neil Blumberg
- Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Richard P Phipps
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA ; Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA ; Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| |
Collapse
|
18
|
Klockenbusch C, Walsh GM, Brown LM, Hoffman MD, Ignatchenko V, Kislinger T, Kast J. Global proteome analysis identifies active immunoproteasome subunits in human platelets. Mol Cell Proteomics 2014; 13:3308-19. [PMID: 25146974 DOI: 10.1074/mcp.m113.031757] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
The discovery of new functions for platelets, particularly in inflammation and immunity, has expanded the role of these anucleate cell fragments beyond their primary hemostatic function. Here, four in-depth human platelet proteomic data sets were generated to explore potential new functions for platelets based on their protein content and this led to the identification of 2559 high confidence proteins. During a more detailed analysis, consistently high expression of the proteasome was discovered, and the composition and function of this complex, whose role in platelets has not been thoroughly investigated, was examined. Data set mining resulted in identification of nearly all members of the 26S proteasome in one or more data sets, except the β5 subunit. However, β5i, a component of the immunoproteasome, was identified. Biochemical analyses confirmed the presence of all catalytically active subunits of the standard 20S proteasome and immunoproteasome in human platelets, including β5, which was predominantly found in its precursor form. It was demonstrated that these components were assembled into the proteasome complex and that standard proteasome as well as immunoproteasome subunits were constitutively active in platelets. These findings suggest potential new roles for platelets in the immune system. For example, the immunoproteasome may be involved in major histocompatibility complex I (MHC I) peptide generation, as the MHC I machinery was also identified in our data sets.
Collapse
Affiliation(s)
- Cordula Klockenbusch
- From the ‡The Biomedical Research Centre, 2222 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
| | - Geraldine M Walsh
- From the ‡The Biomedical Research Centre, 2222 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; §The Centre for Blood Research, 2350 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
| | - Lyda M Brown
- From the ‡The Biomedical Research Centre, 2222 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
| | - Michael D Hoffman
- From the ‡The Biomedical Research Centre, 2222 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; ¶The Department of Chemistry, 2036 Main Mall, University of British Columbia, Vancouver, BC V6T 1Z1, Canada
| | - Vladimir Ignatchenko
- ‖Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada
| | - Thomas Kislinger
- ‖Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada; **Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Juergen Kast
- From the ‡The Biomedical Research Centre, 2222 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; §The Centre for Blood Research, 2350 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; ¶The Department of Chemistry, 2036 Main Mall, University of British Columbia, Vancouver, BC V6T 1Z1, Canada;
| |
Collapse
|
19
|
Burkhart JM, Gambaryan S, Watson SP, Jurk K, Walter U, Sickmann A, Heemskerk JWM, Zahedi RP. What can proteomics tell us about platelets? Circ Res 2014; 114:1204-19. [PMID: 24677239 DOI: 10.1161/circresaha.114.301598] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
More than 130 years ago, it was recognized that platelets are key mediators of hemostasis. Nowadays, it is established that platelets participate in additional physiological processes and contribute to the genesis and progression of cardiovascular diseases. Recent data indicate that the platelet proteome, defined as the complete set of expressed proteins, comprises >5000 proteins and is highly similar between different healthy individuals. Owing to their anucleate nature, platelets have limited protein synthesis. By implication, in patients experiencing platelet disorders, platelet (dys)function is almost completely attributable to alterations in protein expression and dynamic differences in post-translational modifications. Modern platelet proteomics approaches can reveal (1) quantitative changes in the abundance of thousands of proteins, (2) post-translational modifications, (3) protein-protein interactions, and (4) protein localization, while requiring only small blood donations in the range of a few milliliters. Consequently, platelet proteomics will represent an invaluable tool for characterizing the fundamental processes that affect platelet homeostasis and thus determine the roles of platelets in health and disease. In this article we provide a critical overview on the achievements, the current possibilities, and the future perspectives of platelet proteomics to study patients experiencing cardiovascular, inflammatory, and bleeding disorders.
Collapse
Affiliation(s)
- Julia M Burkhart
- From the Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund, Germany (J.M.B., A.S., R.P.Z); Institut für Klinische Biochemie und Pathobiochemie, Universitätsklinikum Würzburg, Würzburg, Germany (S.G.); Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia (S.G.); Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.P.W.); Center for Thrombosis and Hemostasis, Universitätsklinikum der Johannes Gutenberg-Universität Mainz, Mainz, Germany (K.J., U.W.); Medizinisches Proteom Center, Ruhr Universität Bochum, Bochum, Germany (A.S.); Department of Chemistry, College of Physical Sciences, University of Aberdeen, Aberdeen, Scotland, United Kingdom (A.S.); and Department of Biochemistry, CARIM, Maastricht University, Maastricht, The Netherlands (J.W.M.H.)
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Polkinghorne VR, Standeven KF, Schroeder V, Carter AM. Role of proteomic technologies in understanding risk of arterial thrombosis. Expert Rev Proteomics 2014; 6:539-50. [DOI: 10.1586/epr.09.75] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
21
|
Prudent M, Tissot JD, Lion N. Proteomics of blood and derived products: what’s next? Expert Rev Proteomics 2014; 8:717-37. [DOI: 10.1586/epr.11.58] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
22
|
Ding SJ, Qian WJ, Smith RD. Quantitative proteomic approaches for studying phosphotyrosine signaling. Expert Rev Proteomics 2014; 4:13-23. [PMID: 17288512 DOI: 10.1586/14789450.4.1.13] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Protein tyrosine phosphorylation is a fundamental mechanism for controlling many aspects of cellular processes, as well as aspects of human health and diseases. Compared with phosphoserine and phosphothreonine, phosphotyrosine signaling is more tightly regulated, but often more challenging to characterize, due to significantly lower levels of tyrosine phosphorylation (i.e., a relative abundance of 1800:200:1 was estimated for phosphoserine/phosphothreonine/phosphotyrosine in vertebrate cells). In this review, we outline recent advances in analytical methodologies for enrichment, identification and accurate quantitation of tyrosine-phosphorylated proteins and peptides. Advances in antibody-based technologies, capillary liquid chromatography coupled with mass spectrometry, and various stable isotope labeling strategies are discussed, as well as non-mass spectrometry-based methods, such as those using protein/peptide arrays. As a result of these advances, powerful tools now have the power to crack signal transduction codes at the system level, and provide a basis for discovering novel drug targets for human diseases.
Collapse
Affiliation(s)
- Shi-Jian Ding
- Pacific Northwest National Laboratory, Biological Science Division & Environmental Molecular Sciences Laboratory, Richland, WA 99352, USA.
| | | | | |
Collapse
|
23
|
|
24
|
Zimman A, Titz B, Komisopoulou E, Biswas S, Graeber TG, Podrez EA. Phosphoproteomic analysis of platelets activated by pro-thrombotic oxidized phospholipids and thrombin. PLoS One 2014; 9:e84488. [PMID: 24400094 PMCID: PMC3882224 DOI: 10.1371/journal.pone.0084488] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Accepted: 11/15/2013] [Indexed: 11/19/2022] Open
Abstract
Specific oxidized phospholipids (oxPCCD36) promote platelet hyper-reactivity and thrombosis in hyperlipidemia via the scavenger receptor CD36, however the signaling pathway(s) induced in platelets by oxPCCD36 are not well defined. We have employed mass spectrometry-based tyrosine, serine, and threonine phosphoproteomics for the unbiased analysis of platelet signaling pathways induced by oxPCCD36 as well as by the strong physiological agonist thrombin. oxPCCD36 and thrombin induced differential phosphorylation of 115 proteins (162 phosphorylation sites) and 181 proteins (334 phosphorylation sites) respectively. Most of the phosphoproteome changes induced by either agonist have never been reported in platelets; thus they provide candidates in the study of platelet signaling. Bioinformatic analyses of protein phosphorylation dependent responses were used to categorize preferential motifs for (de)phosphorylation, predict pathways and kinase activity, and construct a phosphoproteome network regulating integrin activation. A putative signaling pathway involving Src-family kinases, SYK, and PLCγ2 was identified in platelets activated by oxPCCD36. Subsequent ex vivo studies in human platelets demonstrated that this pathway is downstream of the scavenger receptor CD36 and is critical for platelet activation by oxPCCD36. Our results provide multiple insights into the mechanism of platelet activation and specifically in platelet regulation by oxPCCD36.
Collapse
Affiliation(s)
- Alejandro Zimman
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
| | - Bjoern Titz
- Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center and California NanoSystems Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
| | - Evangelia Komisopoulou
- Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center and California NanoSystems Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
| | - Sudipta Biswas
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
| | - Thomas G. Graeber
- Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center and California NanoSystems Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
| | - Eugene A. Podrez
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
- * E-mail:
| |
Collapse
|
25
|
Dütting S, Vögtle T, Morowski M, Schiessl S, Schäfer CM, Watson SK, Hughes CE, Ackermann JA, Radtke D, Hermanns HM, Watson SP, Nitschke L, Nieswandt B. Growth factor receptor-bound protein 2 contributes to (hem)immunoreceptor tyrosine-based activation motif-mediated signaling in platelets. Circ Res 2013; 114:444-453. [PMID: 24265393 DOI: 10.1161/circresaha.114.302670] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
RATIONALE Platelets are anuclear cell fragments derived from bone marrow megakaryocytes (MKs) that safeguard vascular integrity but may also cause pathological vessel occlusion. One major pathway of platelet activation is triggered by 2 receptors that signal through an (hem)immunoreceptor tyrosine-based activation motif (ITAM), the activating collagen receptor glycoprotein (GP) VI and the C-type lectin-like receptor 2 (CLEC-2). Growth factor receptor-bound protein 2 (Grb2) is a ubiquitously expressed adapter molecule involved in signaling processes of numerous receptors in different cell types, but its function in platelets and MKs is unknown. OBJECTIVE We tested the hypothesis that Grb2 is a crucial adapter protein in (hem)immunoreceptor tyrosine-based activation motif signaling in platelets. METHODS AND RESULTS Here, we show that genetic ablation of Grb2 in MKs and platelets did not interfere with MK differentiation or platelet production. However, Grb2-deficiency severely impaired glycoprotein VI-mediated platelet activation because of defective stabilization of the linker of activated T-cell (LAT) signalosome and activation of downstream signaling proteins that resulted in reduced adhesion, aggregation, and coagulant activity on collagen in vitro. Similarly, CLEC-2-mediated signaling was impaired in Grb2-deficient platelets, whereas the cells responded normally to stimulation of G protein-coupled receptors. In vivo, this selective (hem)immunoreceptor tyrosine-based activation motif signaling defect resulted in prolonged bleeding times but affected arterial thrombus formation only after concomitant treatment with acetylsalicylic acid, indicating that defective glycoprotein VI signaling in the absence of Grb2 can be compensated through thromboxane A2-induced G protein-coupled receptor signaling pathways. CONCLUSIONS These results reveal an important contribution of Grb2 in (hem)immunoreceptor tyrosine-based activation motif signaling in platelets in hemostasis and thrombosis by stabilizing the LAT signalosome.
Collapse
Affiliation(s)
- Sebastian Dütting
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Timo Vögtle
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Martina Morowski
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Sarah Schiessl
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Carmen M Schäfer
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Stephanie K Watson
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Craig E Hughes
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Jochen A Ackermann
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Daniel Radtke
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Heike M Hermanns
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Steve P Watson
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Lars Nitschke
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| | - Bernhard Nieswandt
- Department of Experimental Biomedicine, University Hospital Würzburg (S.D., T.V., M.M., S.S., B.N.) and Rudolf Virchow Center for Experimental Biomedicine (S.D., T.V., C.M.S., H.M.H., B.N.), University of Würzburg, Würzburg, Germany; Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom (S.K.W., C.E.H., S.P.W.); and Department of Biology, Division of Genetics, University of Erlangen, Erlangen, Germany (J.A.A., D.R., L.N.)
| |
Collapse
|
26
|
Senis YA. Protein-tyrosine phosphatases: a new frontier in platelet signal transduction. J Thromb Haemost 2013; 11:1800-13. [PMID: 24015866 DOI: 10.1111/jth.12359] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Indexed: 08/31/2023]
Abstract
Platelet activation must be tightly controlled in order to allow platelets to respond rapidly to vascular injury and prevent thrombosis from occurring. Protein-tyrosine phosphorylation is one of the main ways in which activation signals are transmitted in platelets. Although much is known about the protein-tyrosine kinases (PTKs) that initiate and propagate activation signals, relatively little is known about the protein-tyrosine phosphatases (PTPs) that modulate these signals in platelets. PTPs are a family of enzymes that dephosphorylate tyrosine residues in proteins and regulate signals transmitted within cells. PTPs have been implicated in a variety of pathological conditions, including cancer, diabetes and autoimmunity, but their functions in hemostasis and thrombosis remain largely undefined. Exciting new findings from a number of groups have revealed that PTPs are in fact critical regulators of platelet activation and thrombosis. The primary aim of this review is to highlight the unique and important functions of PTPs in regulating platelet activity. Establishing the functions of PTPs in platelets is essential to better understand the molecular basis of thrombosis and may lead to the development of improved antithrombotic therapies.
Collapse
Affiliation(s)
- Y A Senis
- Centre for Cardiovascular and Respiratory Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK
| |
Collapse
|
27
|
Bleijerveld OB, van Holten TC, Preisinger C, van der Smagt JJ, Farndale RW, Kleefstra T, Willemsen MH, Urbanus RT, de Groot PG, Heck AJ, Roest M, Scholten A. Targeted Phosphotyrosine Profiling of Glycoprotein VI Signaling Implicates Oligophrenin-1 in Platelet Filopodia Formation. Arterioscler Thromb Vasc Biol 2013; 33:1538-43. [DOI: 10.1161/atvbaha.112.300916] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Objective—
Platelet adhesion to subendothelial collagen is dependent on the integrin α
2
β
1
and glycoprotein VI (GPVI) receptors. The major signaling routes in collagen-dependent platelet activation are outlined; however, crucial detailed knowledge of the actual phosphorylation events mediating them is still limited. Here, we explore phosphotyrosine signaling events downstream of GPVI with site-specific detail.
Approach and Results—
Immunoprecipitations of phosphotyrosine-modified peptides from protein digests of GPVI-activated and resting human platelets were compared by stable isotope-based quantitative mass spectrometry. We surveyed 214 unique phosphotyrosine sites over 2 time points, of which 28 showed a significant increase in phosphorylation on GPVI activation. Among these was Tyr370 of oligophrenin-1 (OPHN1), a Rho GTPase–activating protein. To elucidate the function of OPHN1 in platelets, we performed an array of functional platelet analyses within a small cohort of patients with rare oligophrenia. Because of germline mutations in the
OPHN1
gene locus, these patients lack OPHN1 expression entirely and are in essence a human knockout model. Our studies revealed that among other unaltered properties, patients with oligophrenia show normal P-selectin exposure and α
IIb
β
3
activation in response to GPVI, as well as normal aggregate formation on collagen under shear conditions. Finally, the major difference in OPHN1-deficient platelets turned out to be a significantly reduced collagen-induced filopodia formation.
Conclusions—
In-depth phosphotyrosine screening revealed many novel signaling recipients downstream of GPVI activation uncovering a new level of detail within this important pathway. To illustrate the strength of such data, functional follow-up of OPHN1 in human platelets deficient in this protein showed reduced filopodia formation on collagen, an important parameter of platelet hemostatic function.
Collapse
Affiliation(s)
- Onno B. Bleijerveld
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Thijs C. van Holten
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Christian Preisinger
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Jasper J. van der Smagt
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Richard W. Farndale
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Tjitske Kleefstra
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Marjolein H. Willemsen
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Rolf T. Urbanus
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Philip G. de Groot
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Albert J.R. Heck
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Mark Roest
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| | - Arjen Scholten
- From the Biomolecular Mass Spectrometry and Proteomics and Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Netherlands Proteomics Centre, Utrecht, The Netherlands (O.B.B., C.P., A.J.R.H., A.S.); Departments of Clinical Chemistry and Haematology (T.C.v.H., R.T.U., P.G.d.G., M.R.) and Medical Genetics (J.J.v.d.S.), University Medical Center Utrecht, Utrecht, The Netherlands
| |
Collapse
|
28
|
Wright B, Stanley RG, Kaiser WJ, Gibbins JM. The integration of proteomics and systems approaches to map regulatory mechanisms underpinning platelet function. Proteomics Clin Appl 2013. [DOI: 10.1002/prca.201200095] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Bernice Wright
- Institute for Cardiovascular and Metabolic Research (ICMR), School of Biological Sciences; University of Reading; Reading; Berkshire; UK
| | - Ronald G. Stanley
- Institute for Cardiovascular and Metabolic Research (ICMR), School of Biological Sciences; University of Reading; Reading; Berkshire; UK
| | - William J. Kaiser
- Institute for Cardiovascular and Metabolic Research (ICMR), School of Biological Sciences; University of Reading; Reading; Berkshire; UK
| | - Jonathan M. Gibbins
- Institute for Cardiovascular and Metabolic Research (ICMR), School of Biological Sciences; University of Reading; Reading; Berkshire; UK
| |
Collapse
|
29
|
|
30
|
Hughes CE, Radhakrishnan UP, Lordkipanidzé M, Egginton S, Dijkstra JM, Jagadeeswaran P, Watson SP. G6f-like is an ITAM-containing collagen receptor in thrombocytes. PLoS One 2012; 7:e52622. [PMID: 23285115 PMCID: PMC3528668 DOI: 10.1371/journal.pone.0052622] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Accepted: 11/20/2012] [Indexed: 01/22/2023] Open
Abstract
Collagen activates mammalian platelets through a complex of the immunoglobulin (Ig) receptor GPVI and the Fc receptor γ-chain, which has an immunoreceptor tyrosine-based activation motif (ITAM). Cross-linking of GPVI mediates activation through the sequential activation of Src and Syk family kinases and activation of PLCγ2. Nucleated thrombocytes in fish are activated by collagen but lack an ortholog of GPVI. In this study we show that collagen activates trout thrombocytes in whole blood and under flow conditions through a Src kinase driven pathway. We identify the Ig receptor G6f-like as a collagen receptor and demonstrate in a cell line assay that it signals through its cytoplasmic ITAM. Using a morpholino for in vivo knock-down of G6f-like levels in zebrafish, we observed a marked delay or absence of occlusion of the venous and arterial systems in response to laser injury. Thus, G6f-like is a physiologically relevant collagen receptor in fish thrombocytes which signals through the same ITAM-based signalling pathway as mammalian GPVI, providing a novel example of convergent evolution.
Collapse
Affiliation(s)
- Craig E Hughes
- Centre for Cardiovascular Sciences, Institute for Biomedical Research, The College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
| | | | | | | | | | | | | |
Collapse
|
31
|
A detailed proteomic analysis of rhodocytin-activated platelets reveals novel clues on the CLEC-2 signalosome: implications for CLEC-2 signaling regulation. Blood 2012; 120:e117-26. [DOI: 10.1182/blood-2012-09-456004] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Abstract
C-type lectin-like receptor 2 (CLEC-2) is an essential platelet-activating receptor in hemostasis and thrombosis that is activated by the snake venom rhodocytin. We present here a differential proteomic analysis of basal and rhodocytin-activated platelets with the aim of providing novel clues on CLEC-2 signaling regulation. Proteome analysis was based on 2D-DIGE, phosphotyrosine immunoprecipitations followed by 1D SDS-PAGE and mass spectrometry. Protein-protein interactions were studied by coimmunoprecipitations and a systems biology approach. Overall, we identified 132 proteins differentially regulated after CLEC-2 platelet activation, including most of the major players reported so far in the signaling cascade. In addition, we identified various proteins not previously known to participate in CLEC-2 signaling, such as the adapters Dok-2 and ADAP, tyrosine kinase Fer, and tyrosine phosphatase SHIP-1. We also report an increased association between Dok-2 and SHIP-1 in rhodocytin-stimulated platelets, which might negatively regulate CLEC-2 signaling. Moreover, we also present a comparative analysis of proteomic data for CLEC-2 and glycoprotein VI signaling. We think that our data provide thrombosis-relevant information on CLEC-2 signaling regulation, contributing to a better understanding of this important signaling cascade.
Collapse
|
32
|
Response to "Platelets proteomics in transfusion medicine: a reality with challenging but promising future". BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2012; 11:316. [PMID: 23245716 DOI: 10.2450/2012.0175-12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Accepted: 10/08/2012] [Indexed: 01/21/2023]
|
33
|
Comparative analysis of platelet-derived microparticles reveals differences in their amount and proteome depending on the platelet stimulus. J Proteomics 2012; 76 Spec No.:287-96. [DOI: 10.1016/j.jprot.2012.02.030] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2011] [Revised: 02/11/2012] [Accepted: 02/22/2012] [Indexed: 01/14/2023]
|
34
|
Zufferey A, Fontana P, Reny JL, Nolli S, Sanchez JC. Platelet proteomics. MASS SPECTROMETRY REVIEWS 2012; 31:331-351. [PMID: 22009795 DOI: 10.1002/mas.20345] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/25/2011] [Revised: 06/10/2011] [Accepted: 06/10/2011] [Indexed: 05/31/2023]
Abstract
Platelets are small cell fragments, produced by megakaryocytes, in the bone marrow. They play an important role in hemostasis and diverse thrombotic disorders. They are therefore primary targets of antithrombotic therapies. They are implicated in several pathophysiological pathways, such as inflammation or wound repair. In blood circulation, platelets are activated by several pathways including subendothelial matrix and thrombin, triggering the formation of the platelet plug. Studying their proteome is a powerful approach to understand their biology and function. However, particular attention must be paid to different experimental parameters, such as platelet quality and purity. Several technologies are involved during the platelet proteome processing, yielding information on protein identification, characterization, localization, and quantification. Recent technical improvements in proteomics combined with inter-disciplinary strategies, such as metabolomic, transcriptomics, and bioinformatics, will help to understand platelets biological mechanisms. Therefore, a comprehensive analysis of the platelet proteome under different environmental conditions may contribute to elucidate complex processes relevant to platelet function regarding bleeding disorders or platelet hyperreactivity and identify new targets for antiplatelet therapy.
Collapse
Affiliation(s)
- Anne Zufferey
- Division of Angiology and Haemostasis, Department of Internal Medicine, Faculty of Medicine, University Hospitals of Geneva, Geneva, Switzerland
| | | | | | | | | |
Collapse
|
35
|
Abstract
Platelets pose unique challenges to cell biologists due to their lack of nucleus and low levels of messenger RNA. Platelets cannot be cultured in great abundance or manipulated using common recombinant DNA technologies. As a result, platelet research has lagged behind that of nucleated cells. The advent of mass spectrometry and its application to protein biochemistry brought with it great hopes for the platelet community that are now being realized. This technology is ideally suited for identifying low-abundance proteins, protein-protein interactions, and post-translational modifications in complex protein mixtures. Over the past 10 years, proteomics has delivered in many ways, providing platelet biologists with a comprehensive list of proteins expressed in platelets, information on post-translational modifications, protein interactions and sub-cellular localization. Several novel and important platelet membrane proteins, including CLEC-2, CD148, G6b-B, G6f, and Hsp47, have been identified using proteomics-based approaches. New, more sensitive instrumentation and novel approaches are making it increasingly possible to identify ever lower amounts of proteins. In this chapter we highlight some of the major achievements of platelet proteomics to date, discussing challenges and how they were overcome. We also discuss new frontiers and applications of proteomics to platelets and microparticles in health and disease, as we strive to better understand the molecular mechanisms underlying the platelet response to vascular injury.
Collapse
Affiliation(s)
- Yotis Senis
- Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK.
| | | |
Collapse
|
36
|
Altered proteomic pattern in platelets of rats with sepsis. Blood Cells Mol Dis 2012; 48:30-5. [DOI: 10.1016/j.bcmd.2011.09.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2011] [Revised: 09/26/2011] [Accepted: 09/26/2011] [Indexed: 11/20/2022]
|
37
|
Parguiña AF, Grigorian-Shamagian L, Agra RM, López-Otero D, Rosa I, Alonso J, Teijeira-Fernández E, González-Juanatey JR, García Á. Variations in Platelet Proteins Associated With ST-Elevation Myocardial Infarction. Arterioscler Thromb Vasc Biol 2011; 31:2957-64. [DOI: 10.1161/atvbaha.111.235713] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Our aim in this study was to provide novel information on the molecular mechanisms playing a major role in the unwanted platelet activation associated with ST-elevation myocardial infarction (STEMI).
Methods and Results—
We compared the platelet proteome of 11 STEMI patients to a matched control group of 15 stable chronic ischemic cardiopathy patients. In addition, we did a prospective study to follow the STEMI patients over time. Proteins were separated by high-resolution 2D gel electrophoresis, identified by mass spectrometry, and validated by Western blotting. Platelets from STEMI patients on admission displayed 56 protein spot differences (corresponding to 42 unique genes) compared with the control group. The number of differences decreased with time during the patients' follow-up. Interestingly, the adapter protein CrkL and the active form of Src (phosphorylated in Tyr418) were found to be upregulated in platelets from STEMI patients. Major signaling pathways related to the proteins identified include integrin, integrin-linked kinase, and glycoprotein VI (GPVI) signaling. Interestingly, a study on an independent cohort of patients showed a higher degree of activation of GPVI signaling in STEMI patients.
Conclusion—
CrkL, the active form of Src, and GPVI signaling are upregulated in platelets from STEMI patients.
Collapse
Affiliation(s)
- Andrés F. Parguiña
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Lilian Grigorian-Shamagian
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Rosa M. Agra
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Diego López-Otero
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Isaac Rosa
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Jana Alonso
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Elvis Teijeira-Fernández
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - José Ramón González-Juanatey
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Ángel García
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| |
Collapse
|
38
|
Wright B, Stanley RG, Kaiser WJ, Mills DJ, Gibbins JM. Analysis of protein networks in resting and collagen receptor (GPVI)-stimulated platelet sub-proteomes. Proteomics 2011; 11:4588-92. [DOI: 10.1002/pmic.201100410] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2011] [Revised: 09/12/2011] [Accepted: 09/14/2011] [Indexed: 02/04/2023]
|
39
|
|
40
|
Premsler T, Lewandrowski U, Sickmann A, Zahedi RP. Phosphoproteome analysis of the platelet plasma membrane. Methods Mol Biol 2011; 728:279-290. [PMID: 21468956 DOI: 10.1007/978-1-61779-068-3_19] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Blood platelets are key players standing at the crossroads between physiologically occurring hemostasis and pathologic thrombus formation. As these cellular particles lack a nucleus, intra- and intercellular processes involved in platelet activity and function are almost exclusively regulated on the protein level. In particular, posttranslational protein modification by phosphorylation, which allows for a quick and highly dynamic transduction of cellular signals, is discussed in this context. In addition, since platelet activation and aggregation usually require surface contact with the surrounding tissue, special interest focuses on this contacting region, and hence on the subproteome of the platelet plasma membrane. In this chapter, we present a mass spectrometry-driven approach capable of dealing with the task of platelet plasma membrane proteomics and phosphoproteomics. The outlined protocols include strategies for the isolation and purification of plasma membrane proteins by aqueous two-phase partitioning and subsequent enrichment of phosphopeptides via titanium dioxide chromatography.
Collapse
Affiliation(s)
- Thomas Premsler
- Leibniz - Institute for Analytical Sciences - ISAS - e.V., Dortmund, Germany.
| | | | | | | |
Collapse
|
41
|
Liumbruno G, D’Alessandro A, Grazzini G, Zolla L. How has proteomics informed transfusion biology so far? Crit Rev Oncol Hematol 2010; 76:153-72. [DOI: 10.1016/j.critrevonc.2010.01.009] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2009] [Revised: 12/22/2009] [Accepted: 01/07/2010] [Indexed: 01/06/2023] Open
|
42
|
Májek P, Reicheltová Z, Stikarová J, Suttnar J, Sobotková A, Dyr JE. Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Sci 2010. [PMID: 21073729 DOI: 10.1186/1477-5956-8-56.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Platelets are small anucleated blood particles that play a key role in the control of bleeding. Platelets need to be activated to perform their functions and participate in hemostasis. The process of activation is accompanied by vast protein reorganization and posttranslational modifications. The goal of this study was to identify changes in proteins in platelets activated by different agonists. Platelets were activated by three different agonists - arachidonic acid, collagen, and thrombin. 2D SDS-PAGE (pI 4-7) was used to separate platelet proteins. Proteomes of activated and resting platelets were compared with each other by Progenesis SameSpots statistical software; and proteins were identified by nanoLC-MS/MS. RESULTS 190 spots were found to be significantly different. Of these, 180 spots were successfully identified and correspond to 144 different proteins. Five proteins were found that had not previously been identified in platelets: protein CDV3 homolog, protein ETHE1, protein LZIC, FGFR1 oncogene partner 2, and guanine nucleotide-binding protein subunit beta-5. Using spot expression profile analysis, we found two proteins (WD repeat-containing protein 1 and mitochondrial glycerol-3-phosphate dehydrogenase) that may be part of thrombin specific activation or signal transduction pathway(s). CONCLUSIONS Our results, characterizing the differences within proteins in both activated (by various agonists) and resting platelets, can thus contribute to the basic knowledge of platelets and to the understanding of the function and development of new antiplatelet drugs.
Collapse
Affiliation(s)
- Pavel Májek
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
| | | | | | | | | | | |
Collapse
|
43
|
Májek P, Reicheltová Z, Stikarová J, Suttnar J, Sobotková A, Dyr JE. Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Sci 2010; 8:56. [PMID: 21073729 PMCID: PMC2996359 DOI: 10.1186/1477-5956-8-56] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2010] [Accepted: 11/12/2010] [Indexed: 12/27/2022] Open
Abstract
Background Platelets are small anucleated blood particles that play a key role in the control of bleeding. Platelets need to be activated to perform their functions and participate in hemostasis. The process of activation is accompanied by vast protein reorganization and posttranslational modifications. The goal of this study was to identify changes in proteins in platelets activated by different agonists. Platelets were activated by three different agonists - arachidonic acid, collagen, and thrombin. 2D SDS-PAGE (pI 4-7) was used to separate platelet proteins. Proteomes of activated and resting platelets were compared with each other by Progenesis SameSpots statistical software; and proteins were identified by nanoLC-MS/MS. Results 190 spots were found to be significantly different. Of these, 180 spots were successfully identified and correspond to 144 different proteins. Five proteins were found that had not previously been identified in platelets: protein CDV3 homolog, protein ETHE1, protein LZIC, FGFR1 oncogene partner 2, and guanine nucleotide-binding protein subunit beta-5. Using spot expression profile analysis, we found two proteins (WD repeat-containing protein 1 and mitochondrial glycerol-3-phosphate dehydrogenase) that may be part of thrombin specific activation or signal transduction pathway(s). Conclusions Our results, characterizing the differences within proteins in both activated (by various agonists) and resting platelets, can thus contribute to the basic knowledge of platelets and to the understanding of the function and development of new antiplatelet drugs.
Collapse
Affiliation(s)
- Pavel Májek
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
| | | | | | | | | | | |
Collapse
|
44
|
Fernández Parguiña A, Grigorian-Shamajian L, Agra RM, Teijeira-Fernández E, Rosa I, Alonso J, Viñuela-Roldán JE, Seoane A, González-Juanatey JR, García Á. Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One 2010; 5:e13404. [PMID: 20976234 PMCID: PMC2954807 DOI: 10.1371/journal.pone.0013404] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2010] [Accepted: 09/22/2010] [Indexed: 01/08/2023] Open
Abstract
Background Platelets play a fundamental role in pathological events underlying acute coronary syndrome (ACS). Because platelets do not have a nucleus, proteomics constitutes an optimal approach to follow platelet molecular events associated with the onset of the acute episode. Methodology/Principal Findings We performed the first high-resolution two-dimensional gel electrophoresis-based proteome analysis of circulating platelets from patients with non-ST segment elevation ACS (NSTE-ACS). Proteins were identified by mass spectrometry and validations were by western blotting. Forty protein features (corresponding to 22 unique genes) were found to be differentially regulated between NSTE-ACS patients and matched controls with chronic ischemic cardiopathy. The number of differences decreased at day 5 (28) and 6 months after the acute event (5). Interestingly, a systems biology approach demonstrated that 16 of the 22 differentially regulated proteins identified are interconnected as part of a common network related to cell assembly and organization and cell morphology, processes very related to platelet activation. Indeed, 14 of those proteins are either signaling or cytoskeletal, and nine of them are known to participate in platelet activation by αIIbβ3 and/or GPVI receptors. Several of the proteins identified participate in platelet activation through post-translational modifications, as shown here for ILK, Src and Talin. Interestingly, the platelet-secreted glycoprotein SPARC was down-regulated in NSTE-ACS patients compared to stable controls, which is consistent with a secretion process from activated platelets. Conclusions/Significance The present study provides novel information on platelet proteome changes associated with platelet activation in NSTE-ACS, highlighting the presence of proteins involved in platelet signaling. This investigation paves the way for future studies in the search for novel platelet-related biomarkers and drug targets in ACS.
Collapse
Affiliation(s)
- Andrés Fernández Parguiña
- Departamento de Farmacoloxía, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Lilian Grigorian-Shamajian
- Servicio de Cardiología y Unidad Coronaria, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
- Servicio de Cardiología, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
| | - Rosa M. Agra
- Servicio de Cardiología y Unidad Coronaria, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
| | - Elvis Teijeira-Fernández
- Servicio de Cardiología y Unidad Coronaria, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
| | - Isaac Rosa
- Departamento de Farmacoloxía, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Jana Alonso
- Laboratorio de Proteómica, Instituto de Investigaciones Sanitarias, Hospital Clínico Universitario, Santiago de Compostela, Spain
| | - Juan E. Viñuela-Roldán
- Laboratorio de Inmunología, Hospital Clínico Universitario, Santiago de Compostela, Spain
| | - Ana Seoane
- Servicio de Cardiología y Unidad Coronaria, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
| | - José Ramón González-Juanatey
- Servicio de Cardiología y Unidad Coronaria, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
| | - Ángel García
- Departamento de Farmacoloxía, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- * E-mail:
| |
Collapse
|
45
|
Martinez-Pinna R, Barbas C, Blanco-Colio LM, Tunon J, Ramos-Mozo P, Lopez JA, Meilhac O, Michel JB, Egido J, Martin-Ventura JL. Proteomic and metabolomic profiles in atherothrombotic vascular disease. Curr Atheroscler Rep 2010; 12:202-8. [PMID: 20425260 DOI: 10.1007/s11883-010-0102-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Atherothrombosis remains a major cause of morbidity and mortality in the western world. The underlying processes associated with clinical expression of atherothrombosis include oxidative stress and proteolysis in relation to neovascularisation and intraplaque hemorrhages, leading to immuno-inflammatory response, cell death, and extracellular matrix breakdown. The complex biological multifactorial nature of atherothrombosis requires the development of novel technologies that allow the analysis of cellular and molecular processes responsible for the transition to disease phenotypes and the discovery of new diagnostic and prognostic biomarkers. In the present article, we have reviewed recent advances in the application of proteomic and metabolomic techniques to the study of atherothrombosis. We have focused on recent studies analyzing cells involved in hemo-thrombus formation (platelets, red blood cells, and polymorphonuclear cells), as well as tissues, tissue-conditioned media, and plasma of atherothrombotic patients. In the future, the application of these high-throughput technologies, along with imaging techniques, in systems biology approaches will help to individualize medicine.
Collapse
Affiliation(s)
- Roxana Martinez-Pinna
- Vascular Research Laboratory, Instituto de Investigacion Sanitaria, Fundación Jimenez Diaz, Autonoma University, Av. Reyes Católicos 2, 28040, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Yu Y, Leng T, Yun D, Liu N, Yao J, Dai Y, Yang P, Chen X. Global analysis of the rat and human platelet proteome - the molecular blueprint for illustrating multi-functional platelets and cross-species function evolution. Proteomics 2010; 10:2444-57. [PMID: 20443191 DOI: 10.1002/pmic.200900271] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Emerging evidences indicate that blood platelets function in multiple biological processes including immune response, bone metastasis and liver regeneration in addition to their known roles in hemostasis and thrombosis. Global elucidation of platelet proteome will provide the molecular base of these platelet functions. Here, we set up a high-throughput platform for maximum exploration of the rat/human platelet proteome using integrated proteomic technologies, and then applied to identify the largest number of the proteins expressed in both rat and human platelets. After stringent statistical filtration, a total of 837 unique proteins matched with at least two unique peptides were precisely identified, making it the first comprehensive protein database so far for rat platelets. Meanwhile, quantitative analyses of the thrombin-stimulated platelets offered great insights into the biological functions of platelet proteins and therefore confirmed our global profiling data. A comparative proteomic analysis between rat and human platelets was also conducted, which revealed not only a significant similarity, but also an across-species evolutionary link that the orthologous proteins representing "core proteome", and the "evolutionary proteome" is actually a relatively static proteome.
Collapse
Affiliation(s)
- Yanbao Yu
- Department of Chemistry and Institutes of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Ohashi K, Takizawa F, Tokumaru N, Nakayasu C, Toda H, Fischer U, Moritomo T, Hashimoto K, Nakanishi T, Dijkstra JM. A molecule in teleost fish, related with human MHC-encoded G6F, has a cytoplasmic tail with ITAM and marks the surface of thrombocytes and in some fishes also of erythrocytes. Immunogenetics 2010; 62:543-59. [PMID: 20614118 DOI: 10.1007/s00251-010-0460-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2010] [Accepted: 06/17/2010] [Indexed: 12/15/2022]
Abstract
In teleost fish, a novel gene G6F-like was identified, encoding a type I transmembrane molecule with four extracellular Ig-like domains and a cytoplasmic tail with putative tyrosine phosphorylation motifs including YxN and an immunoreceptor tyrosine-based activation motif (ITAM). G6F-like maps to a teleost genomic region where stretches corresponding to human chromosomes 6p (with the MHC), 12p (with CD4 and LAG-3), and 19q are tightly linked. This genomic organization resembles the ancestral "Ur-MHC" proposed for the jawed vertebrate ancestor. The deduced G6F-like molecule shows sequence similarity with members of the CD4/LAG-3 family and with the human major histocompatibility complex-encoded thrombocyte marker G6F. Despite some differences in molecular organization, teleost G6F-like and tetrapod G6F seem orthologous as they map to similar genomic location, share typical motifs in transmembrane and cytoplasmic regions, and are both expressed by thrombocytes/platelets. In the crucian carps goldfish (Carassius auratus auratus) and ginbuna (Carassius auratus langsdorfii), G6F-like was found expressed not only by thrombocytes but also by erythrocytes, supporting that erythroid and thromboid cells in teleost fish form a hematopoietic lineage like they do in mammals. The ITAM-bearing of G6F-like suggests that the molecule plays an important role in cell activation, and G6F-like expression by erythrocytes suggests that these cells have functional overlap potential with thrombocytes.
Collapse
Affiliation(s)
- Ken Ohashi
- Department of Veterinary Medicine, Nihon University, Fujisawa, Kanagawa, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation. Blood 2010; 115:4102-10. [DOI: 10.1182/blood-2009-07-230268] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Abstract
Platelets play a key role in hemostasis and various diseases including arterial thrombosis. Glycoprotein VI (GPVI) mediates adhesion to collagen structures exposed at sites of vascular injury and subsequent platelet activation. We determined the effects of specific activation of GPVI on the human platelet proteome. Isolated human platelets were stimulated with an activating monoclonal antibody specific for GPVI. Platelet proteins were analyzed by 2-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry. We identified 8 differentially abundant proteins associated with cell signaling, metabolism, organization and rearrangement of the cytoskeleton, and membrane trafficking. Differentially abundant proteins included aldose reductase (AR), beta-centractin, charged multivesicular body protein 3, Src substrate cortactin, ERp57, and pleckstrin. Importantly, GPVI-modulated protein abundance was functionally relevant. Correspondingly, AR enzyme activity significantly increased upon GPVI activation and inhibition of AR resulted in reduced platelet aggregation. Furthermore, ERp57 was released upon ligation of platelet GPVI and increased the activity of tissue factor, a major initiator of blood coagulation. In summary, GPVI activation results in differential changes in abundance of platelet proteins, including AR and ERp57, which support platelet aggregation and platelet-dependent coagulation. These results provide further insight into the mechanisms that underlie platelet activation through the GPVI receptor and may help to identify novel pharmacologic targets.
Collapse
|
49
|
Schubert P, Devine DV. De novo protein synthesis in mature platelets: a consideration for transfusion medicine. Vox Sang 2010; 99:112-22. [PMID: 20345520 DOI: 10.1111/j.1423-0410.2010.01333.x] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Platelet function in thrombosis and haemostasis is reasonably well understood at the molecular level with respect to the proteins involved in cellular structure, signalling networks and platelet interaction with clotting factors and other cells. However, the natural history of these proteins has only recently garnered the attention of platelet researchers. De novo protein synthesis in platelets was discovered 40 years ago; however, it was generally dismissed as merely an interesting minor phenomenon until studies over the past few years renewed interest in this aspect of platelet proteins. It is now accepted that anucleate platelets not only have the potential to synthesize proteins, but this capacity seems to be required to fulfil their function. With translational control as the primary mode of regulation, platelets are able to express biologically relevant gene products in a timely and signal-dependent manner. Platelet protein synthesis during storage of platelet concentrates is a nascent area of research. Protein synthesis does occur, although not for all proteins found in the platelet protein profile. Furthermore, mRNA appears to be well preserved under standard storage conditions. Although its significance is not yet understood, the ability to replace proteins may form a type of cellular repair mechanism during storage. Disruption by inappropriate storage conditions or processes that block protein synthesis such as pathogen reduction technologies may have direct effects on the ability of platelets to synthesize proteins during storage.
Collapse
Affiliation(s)
- P Schubert
- Canadian Blood Services and the Centre for Blood Research, University of British Columbia, Vancouver, BC, Canada
| | | |
Collapse
|
50
|
Proteome of platelets in patients with coronary artery disease. Exp Hematol 2010; 38:341-50. [PMID: 20226836 DOI: 10.1016/j.exphem.2010.03.001] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2009] [Revised: 02/26/2010] [Accepted: 03/02/2010] [Indexed: 11/21/2022]
Abstract
OBJECTIVE This study aimed at investigating the protein patterns of platelets from patients with stable or acute coronary atherosclerosis (CAD), in which platelets play a key role. MATERIALS AND METHODS A proteomic approach was adopted to investigate specific protein patterns in platelets of patients with non-ST elevation acute coronary syndrome, stable angina, or of subjects with no history of CAD. RESULTS Six differentially expressed proteins were identified: two involved in energy metabolism (2-oxoglutarate dehydrogenase [OGDH], and lactate dehydrogenase [LDH]); three were associated with cytoskeleton-based processes (gamma-actin, coronin 1B, and pleckstrin); and one involved in protein degradation (proteasome subunit type 8). Expression levels of OGDH and a cleaved form of gamma-actin were significantly higher in the platelets of patients than in controls, whereas that of LDH was higher only in the platelets of patients with acute coronary disease. The increases in protein expression of OGDH and LDH are paralleled by changes in their functional activities. Coronin and proteasome subunit type 8 were less expressed in the platelets of patients, as were the basic isoforms of pleckstrin. CONCLUSION The platelet proteome is altered in CAD patients with stable or acute coronary syndrome possibly because of the ongoing atherosclerotic process. The identified protein changes not previously connected with CAD were an increase in the energy metabolism enzymes and alterations in the proteins associated with cytoskeleton-based processes, both of which indicate platelet activation.
Collapse
|